A more precise approach to biomarker quantification.
Tethys has pioneered a new generation of blood tests based on proteomics, the large-scale study of proteins, to identify specific protein biomarkers implicated in disease development. One of the greatest challenges in developing this new methodology lies in the scarcity of blood samples that have verifiable disease outcomes. Due in part to the company’s past successes, Tethys has gained access to large population cohort studies that track disease outcomes over long periods of time.
Access to this finite supply of samples solved only one part of the challenge, however. Due to the extremely low volume of the samples, a new technology was needed – one that could optimize the yield from each sample so that the most valuable proteins could be identified among thousands of possibilities. The answer to this part of the challenge was Molecular Counting Technology (MCT).14
The advantage of MCT is that it measures single molecules, one by one, using extremely small quantities of serum, so that the greatest number of markers can be screened sensitively and quantitatively.14
MCT enabled the development of the company’s first commercial product, the PreDx® Diabetes Risk Score, which assesses a patients’ risk of developing type 2 diabetes within five years.
Capturing quantitative differences in some of the proteins, Tethys developed a unique, proprietary algorithm for diabetes risk stratification that has been validated in multiple populations. Additional products addressing cardiovascular and other metabolic diseases are in development.
